BACE

Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010 - 2020

27 views | Aug 14 2023

The study analyzed pharmacological treatments for Alzheimer's disease protected in the US Patent Office, revealing a focus on targeting Aβ accumulation and the need for further research to establish the efficacy of the patented molecules. [Read the Full Post]

Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice

64 views | Oct 09 2022

Adrian L Oblak et al. demonstrated the rigorous translational approaches of the MODEL-AD PTC for interrogating potential therapeutics and provided insight into the limitations of verubecestat as a prophylactic intervention for early-stage AD. [Read the Full Post]

An isogenic panel of App knock-in mouse models: Profiling β-secretase inhibition and endosomal abnormalities

64 views | Jun 20 2022

Naoto Watamura et al. found that multiple factors, including elevated C-terminal fragment β (CTF-β) and humanization of Aβ might influence endosomal alterations in vivo. [Read the Full Post]

BACE1 controls synaptic function through modulating release of synaptic vesicles

0 views | Nov 16 2021

Brati Das et al. suggested that a therapy combining BACE1 inhibitors for reducing amyloid deposition and an mGluR1 PAM for counteracting BACE1-mediated synaptic deficits appeared to be an effective approach for treating AD patients. [Read the Full Post]

Spinal beta-amyloid1-42 acts as an endogenous analgesic peptide in CCI-induced neuropathic pain

214 views | Nov 15 2021

Dong Cui et al. suggested that spinal Aβ1-42 acted as an endogenous analgesic peptide through regulating cytokines and Wnt pathways. [Read the Full Post]

BACE1 controls synaptic function through modulating release of synaptic vesicles

386 views | Jul 29 2021

Brati Das et al. suggested that a therapy combining BACE1 inhibitors for reducing amyloid deposition and an mGluR1 PAM for counteracting BACE1-mediated synaptic deficits appeared to be an effective approach for treating AD patients. [Read the Full Post]

Selective Secretase Targeting for Alzheimer's Disease Therapy

304 views | May 05 2021

Alvaro Miranda et al. summarized structures and the activities of the latest compounds designed for AD treatment, with remarkable in vitro, in vivo, and clinical phase activities. [Read the Full Post]

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease

272 views | Nov 27 2020

Michael F Egan et al. thought that verubecestat was associated with increased risk for several types of adverse events. [Read the Full Post]

Quantification and Pharmacokinetic Property of Verubecestat an BACE1 Inhibitor in Rat Plasma

371 views | Jun 29 2020

Qiong Wang et al. designed an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) approach to measure the rat plasma levels of verubecestat with diazepam as the internal standard. [Read the Full Post]

BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines

0 views | Apr 05 2020

Blume T et al. suggested that carefully dosed inhibitors might be therapeutically effective without affecting the structural integrity of excitatory synapses if given at an early disease stage. [Read the Full Post]